ENTREPRENEURIAL PHARMACEUTICAL R&D EXECUTIVE (click to download resume)
To my colleagues and friends:
I'm please to announce that effective the first of March 2013 I assumed the positon of Vice President for Development for the Flatley Discovery Lab (FDL) in Charlestown, MA. The FDL is a privately held, not for profit corporation devoted exclusively to discovering and developing novel therapeutics for cystic fibrosis. In the capacity of VPD I coordinate the FDL team responsible for transitioning candidate small molecules from the laboratory to early phase clinical trials.
Please visit FDL at http://www.flatleydiscoverylab.com
Prior to its acquisition in 2011 Dr. Ferkany was Vice President for Development at Surface Logix, Inc. in Brighton, Massachusetts a position he assumed in 2007. He joined Surface Logix in 2005 as Vice President of Biology bringing over 20 years of experience from the biotechnology, biopharmaceutical and contract research management industries. Prior to joining Surface Logix, Dr. Ferkany served as Senior Vice President for Virtual Drug Development Incorporated, a privately held biotechnology company engaged in developing therapeutic strategies for biodefense. Dr. Ferkany has also served as Vice President and Chief Technical Officer of NovaScreen BioSciences Corporation, (now a division of Perkin/Elmer) an international contract research organization providing screening, profiling and assay development services for pharmaceutical and biotechnology companies worldwide, and for government agencies including the National Institutes of Health. He also headed his own consulting firm focused on regulatory preclinical drug development. He started his career as head of the Central Nervous Research group at Nova Pharmaceutical Corporation, the first successful biotechnology spin-out from the Johns Hopkins University. Dr. Ferkany has a B.S. in Zoology from the University of Michigan, a doctoral degree in Biomedical Sciences from the University of Texas at Houston, and a Masters of Administrative Sciences awarded from the Johns Hopkins University Carey School of Business in Baltimore.
Since the buyout of Surface Logix, Dr. Ferkany has devoted a significant amount of effort to eatablishing Give-A-Buck.org, a novel internet based charity organization which he founded in 2012.
Kim E, Campbell S, Schueller O, Wong E, Cole B, Kuo J, Ellis J, Ferkany J, Sweetnam P.: A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85. doi: 10.1124/jpet.110.177527. Epub 2011 Mar 15.
Ferkany, J. and Williams, M: The Investigational New Drug Application. Current Protocols in Pharmacology,42:9.10.1-9.10.23. © 2008 by John Wiley & Sons, Inc.
Nuttall, J., Thake, D., Lewis, M., Ferkany, J., Romano, J. and Mitchnick, M.: Concentrations of Dapivirine in the Rhesus Macaque and Rabbit Following Once Daily Intravaginal Administration of a Gel Formulation of [14C]Dapivirine for 7 Days. Antimicrob. Agents Chemotherapeutics, 52: 909 -914, 2007.
Short Protocols in Pharmacology and Drug Discovery: A Compendium of Methods from Current Protocols in Pharmacology (S.J. Enna, M. Williams, J. Ferkany, T. Kenakin, and R. Porsolt, eds)., John Wiley & Sons, Inc.,892 pp, 2007
Prince, W., Tong, W., Ferkany, J., Schueller, O. Andersen, G., Kim, E. and Sweetnam, P.: Repeat Dose Treatment with SLx-4090, a Novel Enterocyte Specific MTP Inhibitor, Reduces the Postprandial Triglyceride Response and Lowers LDL in Healthy Volunteers. XVI International Symposium on Drugs Affecting Lipid Metabolism, NY, 2007.
Ellis, J. Bartolozzi, A., Ferkany, J., Foudoulakis, H., Kim, E., Kuo, J., Ruffing, R., Schueller, O., Wong, E., Yang, Y., and Sweetnam, P.: SLx-4090, an Enterocyte Specific Micorsomal Triglyceride Transport Protein (MTP) Inhibitor Lowers LDL Cholesterol and Triglycerides While Raising HDL Cholesterol in Apo E-/- Mice Fed a High Fat Diet., Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference, Chicago, April, 2007.
McCarthy,-Cole, B., Kim, E., Cassalena, D., Bartolozzi, A., Foudoulakis, H., Yang, Y, Campbell, S, Kirk, B., Schueller, O, Grogan, M., Mak, E. McGonigle, S., Wong, E., Ruffing, R., Ellis, J, Prince, W., Ferkany, J. and Sweetnam, P.: From SAMs to Drugs: Application of the Pharmacomer Technology Platform to Small Molecule Drug Discovery. Boston, 2007.
Humphreys, B.D., Ellis, J., Kuo, K. Garcia, A, Schueller, O., Wong, E., McGonigle, S., Ferkany, J., Soeung, S., Bonventre, J. and Sweetnam, Pl: Selective ROCK 2 Inhibition Attenuates Renal Fiborsis in Unilateral Ureteral Obstruction. American Society for Nephrology Meeting, San Diego, Nov., 2006.
Schueller, O., Tong, W., Ferkany, J. and Sweetnam, P.: Selective ROCK2 Inhibition Attenuates Arterial Plaque Formation in an ApoE Knockout Mouse Model. 2006/
Nuttall, J., D Thake, D., Lewis, M., Ferkany, J.,, Romano, J.and Mitchnick, M..: Concentrations of Dapivirine in the Rhesus Macaque and Rabbit Following Once Daily Intravaginal Administration of a Gel Formulation of [14C]Dapivirine for 7 Days. Microbicides 2006 Conference, Cape Town, South Africa (2006).
Sweetnam, P., Bartolozzi, A., Foudoulakis, H., Yang, Y-F., Ferkany, J., Schueller, O., Campbell, S., Wong, E. and Kim, E: SLx-4090 – a novel, intestine-specific MTP inhibitor – for lowering plasma triglyceride levels for the treatment of dyslipidemia.
No front page content has been created yet.